Anticancer drugs that work simultaneously through multiple mechanisms are sought after because of their potential for greater efficacy and robustness to resistance. Researchers at Capital Medical University and Chinese Institutes for Medical Research generated 21 ternary hybrids containing phenylsulfonylfuroxan, b-carboline und hydroxamic acid moieties.
Arginase 1 (Arg1) is a key mediator of immune suppression, and its overexpression has been reported in multiple cancers, including renal cell carcinoma, pancreatic cancer, and head and neck cancer. However, clinical strategies aimed at inhibiting Arg1 function have achieved only limited success.
Radiopharm Theranostics Ltd. has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I trial of its KLK3-targeting radiotherapeutic, RAD-402, for the treatment of metastatic or locally advanced prostate cancer.
At the 2025 annual meeting of the Society for Neuroscience in San Diego this week, Catherine Woolley’s plenary lecture was an unusual combination of debunking and affirming the importance of sex differences in the brain.
Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.
Shanghai Phrontline Biopharma Co. Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting HER2 (erbB2) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory diseases and immunological disorders.
Idorsia Pharmaceuticals Ltd. has identified aryl sulfone and sulfanone derivatives acting as orexin OX2 receptor (HCRTR2) agonists reported to be useful for the treatment of eating disorders, fatigue, Kleine-Levin syndrome, narcolepsy, obesity, pain, and psychiatric and inflammatory disorders, among others.
Inventisbio Co. Ltd. and Inventisbio LLC have synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
RSS
